Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 7/20 | 0.59 |
| ▸ | CYP1B1 | Q16678 | 7/20 | 0.59 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.57 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1045609 | 0.82 | NFE2L2 (0.64) | CYP1A1CYP1B1CYP19A1CYP1A2CYP2D6 | |
| SCHEMBL1045608 | 0.82 | NFE2L2 (0.64) | CYP1A1CYP1B1CYP19A1CYP1A2CYP2D6 | |
| SCHEMBL7862304 | 0.82 | CYP1A1 (0.61) | CYP1A1CYP1B1CYP19A1ABCG2CYP1A2 | |
| SCHEMBL14518617 | 0.82 | CYP1A1 (0.61) | CYP1A1CYP1B1CYP19A1ABCG2CYP1A2 | |
| SCHEMBL8502492 | 0.81 | CYP1A1 (0.56) | CYP1A1CYP1B1CYP19A1ABCG2CYP1A2 | |
| SCHEMBL8502491 | 0.81 | CYP1A1 (0.56) | CYP1A1CYP1B1CYP19A1ABCG2CYP1A2 | |
| SCHEMBL1480652 | 0.79 | CYP1A1 (0.53) | CYP1A1CYP1B1CYP19A1ABCG2CYP1A2 | |
| SCHEMBL8910888 | 0.79 | CYP1A1 (0.56) | CYP1A1CYP1B1CYP19A1ABCG2CYP1A2 | |
| SCHEMBL5182341 | 0.78 | NFE2L2 (0.69) | CYP1A1CYP1B1CYP19A1ABCG2CYP1A2 | |
| SCHEMBL746936 | 0.77 | ABCG2 (0.57) | CYP1A1CYP1B1CYP19A1ABCG2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6656510-B2 | Antidepressants | INDENA S.P.A. (IT) | 2003-12-02 | — | — | US | claimed |
| US-20010020040-A1 | Hyperforin derivatives, use thereof and formulations containing them | INDENA S.P.A. (IT) | 2001-09-06 | — | — | US | claimed |
| EP-1086071-A1 | HYPERFORIN DERIVATIVES, THE USE THEREOF AND FORMULATIONS CONTAINING THEM | INDENA S.p.A. (IT) | 2001-03-28 | — | — | EP | claimed |
| WO-1999064388-A1 | HYPERFORIN DERIVATIVES, THE USE THEREOF AND FORMULATIONS CONTAINING THEM | INDENA S.P.A. (IT) | 1999-12-16 | — | — | WO | claimed |
| JP-57032255-A | — | — | None | — | — | JP | disclosed |
| EP-1607099-A1 | Use of hyperforin derivatives as an antidepressant agent | INDENA S.p.A. (IT) | 2005-12-21 | — | — | EP | disclosed |
| US-6656510-B2 | Antidepressants | INDENA S.P.A. (IT) | 2003-12-02 | — | — | US | disclosed |
| US-20010020040-A1 | Hyperforin derivatives, use thereof and formulations containing them | INDENA S.P.A. (IT) | 2001-09-06 | — | — | US | disclosed |
| EP-1086071-A1 | HYPERFORIN DERIVATIVES, THE USE THEREOF AND FORMULATIONS CONTAINING THEM | INDENA S.p.A. (IT) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999064388-A1 | HYPERFORIN DERIVATIVES, THE USE THEREOF AND FORMULATIONS CONTAINING THEM | INDENA S.P.A. (IT) | 1999-12-16 | — | — | WO | disclosed |
| JP-S5732255-A | TRIMETHOXYPHENYL DERIVATIVE | KOWA CO | 1982-02-20 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020040-A1 | Hyperforin derivatives, use thereof and formulations containing them | CRH, FOS, VIP | CYP1A1 552/4885CYP1B1 245/4885CYP19A1 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.